Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial. (June 2022)
- Record Type:
- Journal Article
- Title:
- Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial. (June 2022)
- Main Title:
- Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial
- Authors:
- Crispiatico, Valeria
Baldanzi, Cinzia
Napoletano, Arianna
Tomasoni, Laura
Tedeschi, Francesca
Groppo, Elisabetta
Rovaris, Marco
Vitali, Chiara
Cattaneo, Davide - Abstract:
- Background: Hypophonia is a prevailing problem in people with multiple sclerosis (PwMS). However, evidence supporting the effectiveness of voice rehabilitation is lacking. Objective: The aim of this study was to identify the most effective method to reduce hypophonia. Methods: In this randomized controlled trial, 44 PwMS were randomized to intensive and high-effort voice treatment groups, the LSVT-LOUD ®, and conventional treatment group. Subjects received 16 treatments (4 sessions/week) lasting 45 minutes. The primary outcome was voice intensity (dB) in monologue, vocalization, and sentences while voice handicap index (VHI) measured voice self-perception. Outcomes were assessed by a blinded observer at baseline, post-treatment, and 15-month follow-up (FU). Results: Linear models revealed a significant post-intervention between-group mean difference in favor of LSVT-LOUD for monologue: +6.3 dB (95% CI: 2.5 to 10.1); vocalization: +7.4 dB (95% CI: 2.3 to 12.5); and sentences: +9.5 dB (95% CI: 4.7 to 14.3). However, 43.7% PwMS in the LSVT-LOUD and 10% in the conventional treatment group obtained a full recovery of voice intensity (>60 dB) post-treatment, Fisher's test = 13.3, p < 0.01. However, these improvements were not maintained at FU. Between-group differences at VHI were −10.8 (95% CI: −21.2 to −0.4) and −11.3 (95% CI: −24.3 to −1.7) in favor of LSVT-LOUD at post and FU. Conclusion: LSVT-LOUD can be a valid treatment to increase voice intensity in PwMS. However, resultsBackground: Hypophonia is a prevailing problem in people with multiple sclerosis (PwMS). However, evidence supporting the effectiveness of voice rehabilitation is lacking. Objective: The aim of this study was to identify the most effective method to reduce hypophonia. Methods: In this randomized controlled trial, 44 PwMS were randomized to intensive and high-effort voice treatment groups, the LSVT-LOUD ®, and conventional treatment group. Subjects received 16 treatments (4 sessions/week) lasting 45 minutes. The primary outcome was voice intensity (dB) in monologue, vocalization, and sentences while voice handicap index (VHI) measured voice self-perception. Outcomes were assessed by a blinded observer at baseline, post-treatment, and 15-month follow-up (FU). Results: Linear models revealed a significant post-intervention between-group mean difference in favor of LSVT-LOUD for monologue: +6.3 dB (95% CI: 2.5 to 10.1); vocalization: +7.4 dB (95% CI: 2.3 to 12.5); and sentences: +9.5 dB (95% CI: 4.7 to 14.3). However, 43.7% PwMS in the LSVT-LOUD and 10% in the conventional treatment group obtained a full recovery of voice intensity (>60 dB) post-treatment, Fisher's test = 13.3, p < 0.01. However, these improvements were not maintained at FU. Between-group differences at VHI were −10.8 (95% CI: −21.2 to −0.4) and −11.3 (95% CI: −24.3 to −1.7) in favor of LSVT-LOUD at post and FU. Conclusion: LSVT-LOUD can be a valid treatment to increase voice intensity in PwMS. However, results suggest the need for FU interventions targeting maintenance. … (more)
- Is Part Of:
- Multiple sclerosis. Volume 28:Number 7(2022)
- Journal:
- Multiple sclerosis
- Issue:
- Volume 28:Number 7(2022)
- Issue Display:
- Volume 28, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 28
- Issue:
- 7
- Issue Sort Value:
- 2022-0028-0007-0000
- Page Start:
- 1081
- Page End:
- 1090
- Publication Date:
- 2022-06
- Subjects:
- Multiple sclerosis -- voice -- speech and language therapy -- acoustic outcomes
Central nervous system -- Diseases -- Periodicals
Myelin sheath -- Diseases -- Periodicals
Inflammation -- Periodicals
Multiple sclerosis -- Periodicals
Central Nervous System Diseases -- Periodicals
Demyelinating Diseases -- Periodicals
Inflammation -- Periodicals
Multiple Sclerosis -- Periodicals
Système nerveux central -- Maladies -- Périodiques
Gaine de myéline -- Maladies -- Périodiques
Inflammation (Pathologie) -- Périodiques
Sclérose en plaques -- Périodiques
Electronic journals
616.834005 - Journal URLs:
- http://msj.sagepub.com/ ↗
http://search.ebscohost.com/login.aspx?direct=true&db=a2h&jid=DZL&site=ehost-live ↗
http://www.uk.sagepub.com/home.nav ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1352-4585;screen=info;ECOIP ↗
http://www.arnoldpublishers.com/journals/pages/mul_scl/13524585.htm ↗ - DOI:
- 10.1177/13524585211051059 ↗
- Languages:
- English
- ISSNs:
- 1352-4585
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20710.xml